Small Cell Lung Cancer

References

• De Greve J., Fedorko J., Battey J., Minna J. Identification of a protein encoded by the 4kb L-MYC mRNA located in the nucleus of small cell lung cancer. Proc ECCO 1987; 4: 1
   Google Scholar
• Little C. D, Nau M. M, Carney D. N, Gazdar A. F, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306: 194
   PubMed Web of Science ®Google Scholar
• Rodenhuis S., van de Wetering M. L, Mooi W. J, Evers S. G, van Zandwijk N., Bos JL. Mutational activation of the K-ras oncogene: a pathogenetic factor in adenocarcinoma of the lung. Proc ECCO 1987; 4: 1
   Google Scholar
• Griffin A., Baylin B. Expression of the c-myb oncogene in human small cell lung carcinoma. Cancer Res 1985; 45: 272
   PubMed Web of Science ®Google Scholar
• Carney D. N, Redmond O., Harford P., Stack J., Ennis J. Bone marrow involvement (BMI) by small cell lung cancer (SCLC) using magnetic resonance imaging (MRI). Proc ASCO 1989; 8: 228
   Google Scholar
• Watanabe J., Okabe T., Fujisawa M., Takaku F., Hiroshashi S., Shimosato Y. Monoclonal antibody that distinguishes small cell lung cancer from non-small cell lung cancer. Cancer Res 1987; 47: 826
   PubMedGoogle Scholar
• Salk D., Fer M., Faubion C., et al. Successful imaging of small cell carcinoma (SCC) with a radiolabeled monoclonal antibody. Proc ASCO 1989; 8: 145
   Google Scholar
• Ganz P. A, Yeung M. P, Wang H. J, Elashoff RM. Evaluation of three biochemical markers for serially monitoring the therapy of small cell lung cancer. J Clin Oncol 1987; 5: 472
   PubMed Web of Science ®Google Scholar
• Anonymous. Report on the 'Leeds Castle' consensus meeting on prognostic factors in small cell lung cancer. Lung Cancer, In press
   Google Scholar
• Albain K., Crowley J., Livingston R. P. rognostic factors in limited small cell (LSC) lung cancer reconsidered: Southwest Oncology Group (SWOG) Studies. Proc ASCO 1989; 8: 225
   Google Scholar
• Splinter T. AW. EORTC 08825: induction vs induction plus maintenance chemotherapy (CT) in small cell lung cancer (SCLC). Definitive evaluation. Proc ASCO 1988; 7: 202
   Google Scholar
• Østerlind K., Hansen H. H, Hansen M., Dombernowsky P., Andersen PK. Long-term disease-free survival in small cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1987; 4: 1307
   Google Scholar
• Spiegelman D., Maurer L. H, Ware J. H, et al. Prognostic factors in small cell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 1989; 7: 344
   PubMedGoogle Scholar
• Karrer K., Shields T., Denck H., et al. Initial surgical resection of small cell lung cancer (SCLC) followed by intensive chemotherapy. Proc ASCO 1989; 8: 221
   Google Scholar
• Birch R., Omura G. A, Greco F. A, Perez CA. Patterns of failure in combined chemotherapy and radiotherapy for limited small cell lung cancer: Southeastern Cancer Study Group Experience. NCI Monographs 1988; 6: 265
   Google Scholar
• Baker R. R, Ettinger D. S, Ruckdeschel J. D, et al. The role of surgery in the management of selected patients with smallcell carcinoma of the lung. J Clin Oncol 1987; 5: 697
   PubMed Web of Science ®Google Scholar
• Williams C. J, McMillan I., Lea R., et al. Surgery after chemotherapy for localized small-cell carcinoma of the lung. J Clin Oncol 1987; 5: 1579
   PubMedGoogle Scholar
• Medical Research Council Lung Cancer Working Party: Radiotherapy alone or with chemotherapy in the treatment of small cell carcinoma of the lung: the results at 36 months. Br J Cancer 1981; 44: 611
   PubMedGoogle Scholar
• Perez C. A, Krauss S., Bartolucci A. A, et al. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung. Cancer 1981; 47: 2407
   PubMedGoogle Scholar
• Bergsagel D. E, Jenkin R. DT, Pringle IF, et al. Lung cancer: clinical trial of radiotherapy alone vs radiotherapy plus cyclophosphamide. Cancer 1972; 30: 621
   PubMedGoogle Scholar
• Malik S. TA. Small cell lung cancer. Randomized trials in cancer: A critical review by sites, M. L Slevin, M. J Staquet. Raven Press, New York 1986; 493
   Google Scholar
• Bork E., Hansen M., Ersbol J., Dombernowsky P., Bergmann B., Hansen HH. A randomized study of teniposide (VM-26) versus vepeside (VP-16) as single agents in previously untreated patients with small cell lung cancer (SCLC) >70 years. Proc ASCO 1989; 8: 229
   Google Scholar
• Giaccone G., Donadio M., Bonardi G., Bagatella M., Testore F., Calciati A. Teniposide (VM26) in small cell lung cancer (SCLC). Influence of time from prior chemotherapy (CT) on response and survival. Proc ASCO 1987; 6: 166
   Google Scholar
• Smith I. E, Harland S. J, Robinson B. A, et al. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985; 69: 43
   PubMedGoogle Scholar
• Kolaric K., Eckhardt S., Kaplan E., Intini C., Schoket Z, Kerpel-Fronius S. High dosage 4-EPI doxorubicin (4-EPI DX) in untreated patients with small cell lung cancer—preliminary results of phase II trial. Proc ASCO 1988; 7: 212
   Google Scholar
• Havemann K., Wolf M., Holle R., et al. Cyclic alternating vs response-orientated alternating chemotherapy in small cell lung cancer (SCLC). Proc ECCO 1987; 4: 3
   Google Scholar
• Jackson D., Cruz J., White D., et al. Cisplatinum in extensive small cell lung cancer (SCLC): a randomized trial by the Piedmont Oncology Association. Proc ASCO 1989; 8: 222
   Google Scholar
• Porter I. LL, II, Johnson D. H, Hainsworth J. D, Hande K. R, Greco FA. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 1985; 69: 479
   PubMedGoogle Scholar
• Einhorn L. H, Crawford J., Birch R., Omura G., Johnson D. H, Greco FA. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988; 6: 451
   PubMed Web of Science ®Google Scholar
• Sculier J. P, Klastersky J., Libert P., et al. A phase III study comparing vindesine plus etoposide with (CEV) or without (EV) cisplatin in patients (PTS) with small cell lung cancer (SSCLC). Proc ASCO 1989; 8: 235
   Google Scholar
• Roth B. J, Johnson D. H, Greco F. A, et al. A phase III trial of etoposide (E) and cisplatin (P) versus cyclophosphamide (C), doxorubicin (A) and vincristine (V) versus, alternation of the two therapies for patients (PTS) with extensive small cell lung cancer (SCLC): preliminary results. Proc ASCO 1989; 8: 225
   Google Scholar
• Roszkowski K., Norzdryn-Plotnicki B., Roszkowski W., Ko HL, Jeljaszewics J., Pulverer G. Small cell lung cancer and immunochemotherapy with propionibacterium granulosum KP 45. J Cancer Res Clin Oncol 1985; 109: 72
   PubMedGoogle Scholar
• Østerlind K., Sørensen S., Hansen H. H, et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 1983; 43: 6085
   PubMed Web of Science ®Google Scholar
• Pedersen A. G, Østerlind K., Vindeløv L., et al. Alternating or continuous chemotherapy of small cell lung cancer (SCC). Proc ASCO 1987; 6: 185
   Google Scholar
• Aisner J., Whitacre M., van Echo D. A, Wiernik PH. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 1982; 66: 221
   PubMedGoogle Scholar
• Tamura T., Fukuoka M., Furuse K., et al. Japanese multicenter randomized trial: cyclophosphamide/adriamycin/vincristine (CAV) versus cisplatinletoposide (PVP) versus CAV alternating with PVP (CAV-PVP) in patients with small cell lung cancer. Proc ASCO 1989; 8: 220
   Google Scholar
• Feld R., Evans W. K, Coy P., et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987; 5: 1401
   PubMed Web of Science ®Google Scholar
• Daniels J. R, Chak L. Y, Sikic B. I, et al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984; 2: 1192
   PubMed Web of Science ®Google Scholar
• Report to the Medical Research Council: Maintenance chemotherapy in small cell lung cancer. Resp Med 1989; 83: 57
   Google Scholar
• Geddes D. M, Law K. S, Spiro S. G, Souhami R. L, Harper P. F, Tobias JS. Quality of life in small cell carcinoma of the lung: a comparison of two chemotherapy regimens using daily diary cards. Proc ECCO 1987; 4: 12
   Google Scholar
• Bakker W., Nijhuis-Heddes J. MA, van Oosterom A. T, Noor-Dijk E. M, Hermans J., Dijkman JH. Combined modality treatment of short duration in small cell lung cancer. Eur J Cancer Clin Oncol 1984; 20: 1033
   PubMedGoogle Scholar
• Cullen M., Morgan D., Gregory W., et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 1986; 17: 157
   PubMedGoogle Scholar
• Clarke S. J, Bell D. R, Woods R. L, Levi JA. Maintenance chemotherapy for small cell carcinoma of the lung: long-term follow-up. Proc ASCO 1989; 8: 248
   Google Scholar
• Ettinger D. S, Mehta C. R, Abeloff M. D, Ruckdeschel J. C, Aisner S. Maintenance chemotherapy versus no maintenance chemotherapy in complete responders following induction chemotherapy in extensive disease (ED) small cell lung cancer (SCLC). Proc ASCO 1987; 6: 175
   Google Scholar
• Harper P. G, Souhami R. L, Ash C. M, Spiro S. G, Tobias J. T, Geddes D. Treatment duration in small cell lung cancer (SCLC): a randomized comparison of 4 versus 8 course of initial chemotherapy (I.Ct.) and/or further chemotherapy on relapse. Proc ECCO 1987; 4: 2
   Google Scholar
• Lopez J. A, Mann J., Grapski R. T, et al. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 1985; 69: 369
   PubMedGoogle Scholar
• Postmus P. E, Berendsen H. H, Splinter T. AW, Burghouts J. TM, Bakker W. EORTC Lung Cancer Cooperative Group: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987; 23: 1409
   PubMedGoogle Scholar
• Vincent M., Evans B., Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21: 45
   PubMed Web of Science ®Google Scholar
• Klasa R., Murray N., Goldman A. Dose intensity (DI) meta-analysis of chemotherapy in small cell carcinoma of the lung (SCCL). Proc ASCO 1988; 7: 202
   Google Scholar
• McVie JG. Autologous bone marrow transplantation (ABMT) and high-dose chemotherapy in small cell lung cancer. Experimental and clinical progress in cancer chemotherapy, F. M Muggia. Martinus Nijhoff Publishers, Boston 1985; 211
   Google Scholar
• Ihde D. C, Deisseroth A. B, Lichter A. S, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 1986; 4: 1443
   PubMed Web of Science ®Google Scholar
• Marangolo M., Rosti G., Argnani M., et al. High-dose VP16 and autologous bone marrow transplantation (ABMT) intensification therapy of small cell lung cancer (SCLC): a pilot study. Proc ASCO 1987; 6
   Google Scholar
• Cornbleet M. A, Gregor A., Leonard R. CF, Smyth JF. Late intensification with high dose melphalan (HDM) + autologous bone marrow rescue (ABMR) in small cell lung cancer (SCLC): an analysis of patterns of failure. Proc ECCO 1987; 4: 6
   Google Scholar
• Humblet Y., Symann M., Bosly A., Francis C., Prignot J. Late intensification (LI) with autologous bone marrow transplantation (ABMT) for small cell lung cancer: a randomized trial. Proc ASCO 1985; 4: 176
   Google Scholar
• Morstyn G., Stuart-Harris R., Bishop J., et al. Optimal scheduling of granulocyte macrophage colony stimulating factor (GM-GSF) for the abrogation of chemotherapy induced neutropenia in small cell lung cancer (SCLC). Proc ASCO 1989; 8: 219
   Google Scholar
• Lyman G. H, Williams C. C, Preston D. The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. New Engl J Med 1980; 302: 257
   PubMed Web of Science ®Google Scholar
• Figueredo A. T, Hryniuk W. M, Strautmanis I., Frank G., Rendell S. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54
   PubMed Web of Science ®Google Scholar
• Schmidt R. E, Hartlapp J. H, Niese D., et al. Reduction of infection frequency by intravenous gammaglobulins during intensive induction therapy for small cell carcinoma of the lung. Infection 1984; 12: 167
   PubMed Web of Science ®Google Scholar
• Glamon G. H, Feld R., Evans WK. Effect of adjuvant central iv hyperdimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treat Rep 1985; 69: 167
   PubMedGoogle Scholar
• Weiner R. S, Kramer B. S, Clamon G. H, et al. Effects of intravenous hyperalimentation during treatment in patients with small cell lung cancer. J Clin Oncol 1985; 3: 949
   PubMedGoogle Scholar
• Twelves C. J, Souhami R. L, Spiro S. G, et al. Cerebral metasta-ses in small cell carcinoma of the lung (SCCL) respond to systemic chemotherapy. Proc ECCO 1987; 4: 3
   Google Scholar
• Giaccone G., Bonardi G., Donadio M., Testore F., Calciati A. Teniposide (VM26) in the treatment of brain metastases from small cell lung cancer (SCLC). Roc ECCO 1987; 4: 5
   Google Scholar
• EORTC Lung Cancer Cooperative Group. Teniposide for brain metastases of small cell lung cancer (SCLC). A phase II study. EORTC 08873. Lung Cancer 1988; 4: 116
   Google Scholar
• Urtasun R. C, Belch A. R, McKinnon S., et al. Small cell lung cancer: initial treatment with sequential hemibody irradiation vs 3-drug systemic chemotherapy. Br J Cancer 1982; 46: 228
   PubMedGoogle Scholar
• Salazar O. M, Creech R. H, Rubin P., et al. Half-body and local chest irradiation as consolidation following response to standard induction chemotherapy for disseminated small cell lung cancer. Int J Radiat Oncol Biol Phys 1980; 6: 1093
   PubMedGoogle Scholar
• Woods R. L, Tattersall M. HN, Fox RM. Hemi-body irradiation (HBI) in 'poor prognosis' small cell lung cancer (SCLC). Proc AACR and ASCO 1981; 502
   Google Scholar
• Beiler D. D, Kane R. C, Bemath A. M, Cashdollar MR. Low dose elective brain irradiation in small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1979; 5: 944
   Google Scholar
• Cox J., Petrovich Z., Paig C., et al. Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Cancer 1978; 42: 1135
   PubMed Web of Science ®Google Scholar
• Eagan R. T, Freytak S., Lee R. E, et al. A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small cell lung cancer. Cancer Clin Trials 1981; 4: 261
   PubMedGoogle Scholar
• Hansen H. H, Dombernowsky P., Hirsch F. R, et al. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. Cancer 1980; 46: 279
   PubMedGoogle Scholar
• Jackson D. V, Richards F, II, Cooper MR. Prophylactic cranial irradiation in small cell carcinoma of the lung. JAMA 1977; 237: 2730
   PubMed Web of Science ®Google Scholar
• Katsenis A. T, Karpasitis N., Giannakakis D., Maragoudakis N., Kiparissiadis P. Elective brain irradiation in patients with small-cell carcinoma of the lung: Preliminary report. Lung Cancer. Int Congress Series. Excerpta Medical. 1982; 558: 277
   Google Scholar
• Seydel H. G, Creech R., Pagano M., et al. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol 1985; 8: 218
   PubMedGoogle Scholar
• Lishner M., Feld R., Sagman U., et al. Late neurological complications after prophylactic cranial irradiation (PCI) in patients (pts) with small cell lung cancer (SCLC): the Toronto experience (1975–1985). Roc ASCO 1989; 8: 224
   Google Scholar
• Frytak S., Eagan R. T, Themeau T. M, et al. Leukoencephalopathy (LE) in patients with small cell lung cancer (SCLC) receiving prophylactic cranial irradiation (PCI). Proc ASCO 1987; 6: 174
   Google Scholar
• Bleehen NM. Management of small cell cancer: radiotherapy. Recent Results in Lung Cancer, W. Duncan. Springer-Verlag. 1984; 65
   Google Scholar
• Hansen H. H, Dobemowsky P., Hansen H. S, Rorth M. Chemotherapy versus chemotherapy plus radiotherapy in regional small cell carcinoma of the lung. A randomized trial. Proc AACR 1979; 277
   Google Scholar
• Perez C. A, Einhorn L., Oldham R. K, et al. For the Southeastem Cancer Study Group: Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984; 2: 1200
   PubMed Web of Science ®Google Scholar
• McCracken J. D, Janaki L., Taylor S. A, Weiss G. B, Crowley J. Concurrent chemoradiotherapy for limited small cell carcinoma of the lung (SCCL). Proc ASCO 1987; 6: 167
   Google Scholar
• Trillet V. Combination chemotherapy (doxorubicin, etoposide, ifosfamide) and hyperfractionated irradiation of the chest for small cell lung cancer (SCLC). Proc ECCO 1987; 4: 8
   Google Scholar
• Tumsi A. T, Glover D. J, Mason B., Alavi J., Fox K. Concurrent twice-daily multi-fied radiotherapy (2XD XRT) and platinum-etoposide chemotherapy (P/E) for limited small cell lung cancer (LSCLC): update 1987. Proc ASCO 1987; 6: 172
   Google Scholar
• Le Chevalier T., Arriagada R., Rufit P., et al. Combined radiotherapy (RT) and chemotherapy (CT) in 156 consecutive patients with limited small cell lung carcinoma (LSCLC). Proc ASCO 1988; 7: 211
   Google Scholar
• Aisner S., Wiemik PH. Chemotherapy versus chemoimmun-otherapy for small cell undifferentiated carcinoma of the lung. Cancer 1980; 46: 2543
   PubMed Web of Science ®Google Scholar
• Cohen M. H, Chretien P. B, Ihde D. C, et al. Thymosin fraction V and intensive combination chemotherapy. JAMA 1979; 241: 1815
   Google Scholar
• Fox R. M, Woods R. L, Tattersall H. M, Basten A. A randomized study of adjuvant immunotherapy with levamisole and corynebacterium parvum in operable non small cell lung cancer. Int J Radiat Oncol Biol Phys 1980; 6: 1032
   Google Scholar
• McCracken J. D, Heilbrun L., White J., et al. Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung. Cancer 1980; 46: 2335
   PubMed Web of Science ®Google Scholar
• Mattson K., Niiranen A., Holsti L., Pyrhonen S., Cantell K. Low-dose natural a interferon as maintenance therapy for small cell lung cancer (SCLC). A phase III study. Proc ASCO 1989; 8: 227
   Google Scholar
• Ludwig Lung Cancer Study Group: Adverse effect of intra-pleural corynebacterium parvum as adjuvant therapy in resected stage I and II non small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985; 89: 842
   PubMedGoogle Scholar
• Maurer L. H, Pajak T., Eaton W., et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a phase III Cancer and Leukemia Group B Study. J Clin Oncol 1985; 3: 969
   PubMed Web of Science ®Google Scholar
• Chahinian A. P, Ware J. H, Zimmer B., et al. Update on antico-agulation with warfarin and on alternating chemotherapy in extensive small cell lung cancer of the lung. Proc ASCO 1985; 4: 191
   Google Scholar
• Zacharski L. R, Henderson W. G, Rickles F. R, et al. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981; 245: 831
   PubMed Web of Science ®Google Scholar